Since Vδ1 T cells are enriched at the tumor site of pancreatic and ovarian tumor cells (3, 18), the different impact of galectin-3 on Vδ1 T cells is of high interest and makes them attractive for γδ T-cell-based immunotherapy. This evidence concerns the gene LGALS3 and neoplasm.